370 likes | 494 Views
E N D
1. For demonstration of interpreting a strong positive interaction see slides 25-30.
2. NPC-9902 Trial on Therapeutic Gain by Concurrent Chemotherapy and/or Accelerated Fractionation for Locally-Advanced Nasopharyngeal Cancer Anne W. M. Lee
for
Hong Kong Nasopharyngeal Cancer Study Group
3. Estimation on Sample & Eligible Patients
4. NPC-9902: Eligibility Criteria
5. Eligibility Criteria
7. RT: Same for all Arms
8. RT: Fractionation
9. Treatment in CRT Arm
10. Statistical Consideration
11. Other End Points
12. Participating Centers
13. Accrual Rate
15. Results
16. Patient Characteristics
17. Tumor Staging
18. Radiotherapy
19. Comparison of Prognostic Factors
20. Major Violation of Protocol
21. Compliance to Chemotherapy
22. Acute Toxicity (Grade >3)
23. Chemotherapy Toxicity in CRT Arm
24. Overall Acute Toxicity (Grade >3)
25. Overall Acute Toxicity (Grade >3)
26. Failure-Free Survival (3-year)
27. Failure-Free Survival (3-year)
28. Hazard Ratio = .11 = 1/9
? Nine-fold decrease in failure with AF + CRT together rather than separately.
But the decrease is a product of three effects:
RT + AF
CRT + CF
RT + CF ------------------------------------------------
CRT + AF
29. That is, the benefit due to CRT + AF being delivered in tandem vs. separately is due to:
The apparent disadvantage of CRT + CF over RT + CF (1.1 increase);
The apparent disadvantage of RT + AF over RT + CF (1.4 increase); and
The advantage of CRT + AF over RT + CF (six-fold reduction):
1.1 ? 1.4 ? 6 = 9, the total interaction effect.
30. A clinically important question: Suppose we dont believe the first two effects we dont believe that acceleration or adding chemotherapy can cause failures, and fix their hazard ratios at 1.0:
What is the significance of the restricted interaction effect, the hazard ratio of 6?
Answer: p = ????.
Modest evidence that AF and CRT do seem to work better together.
31. Locoregional Failure-Free Rate (3-year)
32. Distant Failure-Free Rate (3-year)
33. Disease Status at Last Assessment
34. Overall Survival
35. Progression-Free Survival
36. Late Toxicity (Grade >3)
37. Late Toxicity (Grade >3)
38. Subset Analyses Absolute Gain